| Primary |
| Drug Use For Unknown Indication |
21.5% |
| Osteoporosis |
16.6% |
| Product Used For Unknown Indication |
15.6% |
| Hypoparathyroidism |
7.0% |
| Renal Transplant |
6.3% |
| Hypocalcaemia |
6.0% |
| Renal Failure Chronic |
4.6% |
| Hyperparathyroidism Secondary |
3.6% |
| Hypertension |
3.3% |
| Hypothyroidism |
2.6% |
| Hepatitis C |
1.7% |
| Hyperparathyroidism |
1.7% |
| Hypoparathyroidism Secondary |
1.7% |
| Femur Fracture |
1.3% |
| Parkinson's Disease |
1.3% |
| Prostate Cancer Metastatic |
1.3% |
| Calcium Deficiency |
1.0% |
| Calcium Metabolism Disorder |
1.0% |
| Chronic Hepatitis C |
1.0% |
| Gastritis |
1.0% |
|
| Hypercalcaemia |
19.0% |
| Anaphylactic Shock |
7.1% |
| Death |
7.1% |
| Transient Ischaemic Attack |
6.0% |
| Vomiting |
6.0% |
| Decreased Appetite |
4.8% |
| Renal Failure Acute |
4.8% |
| Renal Impairment |
4.8% |
| Therapeutic Product Contamination |
4.8% |
| White Blood Cell Count Decreased |
4.8% |
| Blood Calcium Decreased |
3.6% |
| Cerebrovascular Accident |
3.6% |
| Platelet Count Decreased |
3.6% |
| Renal Failure |
3.6% |
| Venous Thrombosis |
3.6% |
| Vertigo |
3.6% |
| Anaphylactic Reaction |
2.4% |
| Drug Effect Decreased |
2.4% |
| Erythema Multiforme |
2.4% |
| Hepatic Function Abnormal |
2.4% |
|
| Secondary |
| Drug Use For Unknown Indication |
22.7% |
| Hypoparathyroidism |
14.5% |
| Hypothyroidism |
14.1% |
| Hypertension |
7.9% |
| Renal Transplant |
4.9% |
| Hypocalcaemia |
4.6% |
| Product Used For Unknown Indication |
3.3% |
| Rheumatoid Arthritis |
3.3% |
| Coronary Artery Disease |
3.0% |
| Osteoporosis |
3.0% |
| Diabetes Mellitus |
2.6% |
| Hyperlipidaemia |
2.3% |
| Hyperparathyroidism |
2.3% |
| Hyperthyroidism |
2.3% |
| Cancer Pain |
2.0% |
| Constipation |
1.6% |
| Gastritis |
1.6% |
| Attention Deficit/hyperactivity Disorder |
1.3% |
| Benign Prostatic Hyperplasia |
1.3% |
| Hyperparathyroidism Secondary |
1.3% |
|
| Lenticular Opacities |
10.1% |
| Post Procedural Complication |
10.1% |
| Tinnitus |
10.1% |
| Death |
8.7% |
| Therapeutic Product Contamination |
8.7% |
| Toxic Skin Eruption |
5.8% |
| Angina Pectoris |
4.3% |
| Hypercalcaemia |
4.3% |
| Lung Disorder |
4.3% |
| Medication Residue Present |
4.3% |
| Renal Failure |
4.3% |
| Renal Failure Acute |
4.3% |
| Vomiting |
4.3% |
| Hepatic Function Abnormal |
2.9% |
| Pancreatitis |
2.9% |
| Rash Morbilliform |
2.9% |
| Renal Tubular Disorder |
2.9% |
| Anaemia |
1.4% |
| Coma |
1.4% |
| Confusional State |
1.4% |
|
| Concomitant |
| Product Used For Unknown Indication |
30.0% |
| Drug Use For Unknown Indication |
20.5% |
| Hypertension |
6.8% |
| Rheumatoid Arthritis |
6.3% |
| Osteoporosis |
5.8% |
| Hyperphosphataemia |
4.0% |
| Nuclear Magnetic Resonance Imaging |
3.4% |
| Renal Failure Chronic |
3.0% |
| Prophylaxis |
2.6% |
| Pain |
2.3% |
| Hyperparathyroidism Secondary |
2.0% |
| Renal Transplant |
1.9% |
| Diabetes Mellitus |
1.6% |
| Prophylaxis Against Transplant Rejection |
1.6% |
| Peritoneal Dialysis |
1.6% |
| Constipation |
1.5% |
| Insomnia |
1.5% |
| Nephrogenic Anaemia |
1.3% |
| Gastritis |
1.3% |
| Behcet's Syndrome |
1.1% |
|
| Vomiting |
14.5% |
| Muscular Weakness |
11.9% |
| Pyrexia |
7.1% |
| Weight Decreased |
5.4% |
| Pneumonia |
5.2% |
| Urinary Tract Infection |
5.2% |
| Renal Impairment |
4.8% |
| Therapeutic Response Decreased |
4.8% |
| Anaemia |
4.3% |
| Cardiac Arrest |
3.9% |
| Nephrogenic Systemic Fibrosis |
3.9% |
| Wheezing |
3.7% |
| Death |
3.5% |
| Renal Failure Acute |
3.5% |
| Renal Failure |
3.2% |
| Thrombocytopenia |
3.2% |
| Aplasia Pure Red Cell |
3.0% |
| International Normalised Ratio Increased |
3.0% |
| Rhabdomyolysis |
3.0% |
| Sepsis |
3.0% |
|
| Interacting |
| Chronic Myeloid Leukaemia |
100.0% |
|
|
